MAXCYTE INC
MXCT · NASDAQ
Updated at 2026-10-13 15:06:24
- Today's High
- $1.01
- Today’s Low
- $0.94
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $1.01
- Previous Close
- $0.99
- Volume
- 150.12K
- Market Cap
- $102.69M
- P/E Ratio
- --
- EPS
- $-0.33
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Life Sciences Tools & Services
- Sub-industry
- MEDICAL DEVICES
- Headquarters
- 9713 KEY WEST AVENUE, ROCKVILLE, MD, UNITED STATES, 20850
- Country
- US
- Listing Date
- 2016-03-29
- Fiscal Year End
- December
- Shares Outstanding
- 107.12M
- CIK
- 0001287098
- Website
- www.maxcyte.com
MaxCyte Inc. (MXCT) is a leader in cell-engineering, renowned for its innovative Flow Electroporation® technology that enables efficient and scalable delivery of nucleic acids and proteins into a variety of cell types. The company serves a prestigious clientele, including top biopharmaceutical firms and research institutions, positioning it favorably within the rapidly expanding cell and gene therapy market. MaxCyte's advanced platforms play a crucial role in the development of novel cell-based therapies and vaccines, responding to the growing global demand for transformative healthcare solutions. With a steadfast commitment to enhancing patient outcomes, MaxCyte is poised to capitalize on significant market opportunities in the life sciences sector.
Financial Metrics
Revenue
2026-06-30
$7.27M
2026-03-31
$9.65M
2025-12-31
$7.3M
2025-09-30
$6.82M
Operating Expenses
2026-06-30
$15.82M
2026-03-31
$13.25M
2025-12-31
$13.36M
2025-09-30
$16.88M
Net Income
2026-06-30
-$8.87M
2026-03-31
-$4.75M
2025-12-31
-$9.59M
2025-09-30
-$12.41M
Net Profit Margin
2026-06-30
-122.04%
2026-03-31
-49.21%
2025-12-31
-131.45%
2025-09-30
-181.81%
Earnings Per Share
2026-06-30
$-0.08
2026-03-31
$-0.04
2025-12-31
$-0.06
2025-09-30
$-0.09
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$7.66M
2026-03-31
-$3.7M
2025-12-31
-$8.3M
2025-09-30
-$11.13M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $7.27M | $9.65M | $7.3M | $6.82M |
| Operating Expenses | $15.82M | $13.25M | $13.36M | $16.88M |
| Net Income | -$8.87M | -$4.75M | -$9.59M | -$12.41M |
| Net Profit Margin | -122.04% | -49.21% | -131.45% | -181.81% |
| Earnings Per Share | $-0.08 | $-0.04 | $-0.06 | $-0.09 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$7.66M | -$3.7M | -$8.3M | -$11.13M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.